Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert

Efficacy and safety of instant focus (InFo) lens

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged-Depth-of-Focus II

Session Date/Time: Monday 12/09/2016 | 16:00-18:00

Paper Time: 17:30

Venue: Hall C3

First Author: : J.Blondel SWITZERLAND

Co Author(s): :    E. D'Alessandro   A. Ouabas   A. Mermoud              

Abstract Details


To evaluate the efficacy of the newly designed and patented Invariant Focus (InFo*) intra-ocular lens (IOL). The InFo* lens is said to provide full vision at all distances, regardless of focal length and light conditions


The study was an observational, prospective, longitudinal study. We enrolled a total of 24 patients with cataract, implanting a total of 39 InFo* lenses. These patients were followed for up to 12 months.


Best-corrected visual acuity (BCVA), and uncorrected visual acuity (UCVA) were performed prior to surgery, a week following the surgery, and 3, 6, and 12 months after surgery. In order to evaluate the visual outcome, we assessed the change in UCVA and the number of patients who reported not needing glasses in their daily life. Any possible complaints regarding the implant such as patients referring the presence of halos or glares were noted.


Pre-operatively the mean UCVA for far vision was 0.21±0.13 and mean UCVA for near vision was 0.35±0.20. We found UNVA to have improved at the end of the follow-up period with mean UCVA for far vision being 0.64±0.18 and mean UCVA for near vision being 0.91±0.26. In regards to the use of glasses only two patients reported needing them for their daily activities (mainly due to residual astigmatism). Other two patients reported using glasses for near vision but solely when fatigued.


We have found the InFo IOL to have improved vision at all distances in our patients. However, further research is needed in order to confirm these results including larger cohort studies.

Financial Disclosure:

... has significant investment interest in a company producing, developing or supplying product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to previous